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Abstract
We evaluate the outcomes of irradiation by using three-dimensional radiation therapy (3D-RT) or intensity-modulated
radiotherapy (IMRT) for recurrent and metastatic cervical cancer. Between 2007 and 2010, 50 patients with recurrent and
metastatic cervical cancer were treated using 3D-RT or IMRT. The median time interval between the initial treatment and the
start of irradiation was 12 (6–51) months. Salvage surgery was performed before irradiation in 5 patients, and 38 patients
received concurrent chemotherapy. Sixteen patients underwent 3D-RT, and 34 patients received IMRT. Median follow-up for
all the patients was 18.3 months. Three-year overall survival and locoregional control were 56.1% and 59.7%, respectively.
Three-year progression-free survival and disease-free survival were 65.3% and 64.3%, respectively. Nine patients developed
grade 3 leukopenia. Grade 5 acute toxicity was not observed in any of the patients; however, 2 patients developed Grade 3
late toxicity. 3D-RT or IMRT is effective for the treatment of recurrent and metastatic cervical cancer, with the 3-year overall
survival of 56.1%, and its complications are acceptable. Long-term follow-up and further studies are needed to confirm the
role of 3D-RT or IMRT in the multimodality management of the disease.
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Introduction
Despite improvements in the outcomes of single or combined
modality treatment for achieving higher local control of cervical
cancer, locoregional recurrences or distant metastasis after initial
(surgical or radiation) treatment remain a major therapeutic
challenge. A 10–20% recurrence rate has been reported following
primary surgery or radiotherapy in women with stage IB–IIA
cervical tumors. Moreover, if lymph node metastases are present
at diagnosis or if the tumor is in a locally advanced stage, the local
recurrence rate increases to $70% [1,2,3].
Although chemotherapy remains the major treatment modality
in the management of patients with recurrent and metastatic
cervical cancer, its effectiveness is relative poor comparing to other
gynecologic malignancies. Disruption of blood vessels by operation
or high doses of radiation may lead to lower perfusion of the
relapsed cancer. Although various regimens have been used in
a various studies, the response rates are low and the toxicities are
severe. Cisplatin has emerged as the most active single agent with
overall response rates of 19% [4]. Recent phase III trial has
documented response rates of 29.1%, 25.9%, 22.3% and 23.4%
when cisplatin has been combined with paclitaxel, vinorelbine,
gemcitabine and topotecan, respectively [5]. Despite these
encouraging results, however, most of the responses are partial
and of short duration.
Ingynecologiccancers,wehavealwaysusedconventionalEBRT,
which uses bony landmarks to define the target volume for pelvic
radiotherapy. Treatment is delivered either with anterior and
posterior opposed fields or with a 4-field box technique. There is
a risk of a ‘‘marginal miss’’ using conventional EBRT if tumor falls
outside of traditional field borders established by bony landmarks.
In recent years, development of three-dimensional radiation
therapy (3D-RT) and intensity-modulated radiotherapy (IMRT)
has increased the potential for an improved outcome in cervical
cancer; however, there are few published reports on recurrent and
metastatic cervical cancer. In comparison to conventional EBRT,
3D-RT and IMRT allow a more precise dose distribution
conforming to the target volume and have less normal tissue
morbidity. In particular, IMRT can achieve highly conformal dose
distribution around the target with a steep dose gradient outside
the targets, thus sparing OARs and providing an opportunity for
dose escalation. This is particularly important for the treatment of
recurrent and metastatic disease, especially in patients with
a history of irradiation.
Results
Treatment
Seven patients who had received a prior irradiation treatment
showed out-field relapse (n=4) or PALN metastasis (n=3). Thirty-
nine patients showed bulky recurrence ($3 cm). Eight patients,
including 3 patients who received concomitant IMRT treatment
for the recurrent tumor inside the pelvic region, were treated with
PALN-IMRT with a median dose of 50 Gy. Direct tumor boost
was planned for 13 patients. The prescription dose for PTV1 was
45 Gy, and the median dose of PTV2 was 57 Gy (range, 55–
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tumor boost was 50 Gy (range, 45–64 Gy). All the patients
completed the treatment.
Survival, Systemic, and Locoregional Control
Two patients were lost to follow-up. Median follow-up period
for all the patients was 18.3 months, with a minimum of 8 months
for living patients. The 1-, 2-, and 3-year overall survival rates
were 90.5%, 63.6%, and 56.1%, respectively (Fig. 1). The patient
with the longest follow-up is still disease free at .47 months after
the radiotherapy, with a 5-cm vaginal apex failure. The causes of
death were systemic progression of disease (n=13) and local tumor
progression (n=2). The 1-, 2-, and 3-year local control rates and
progression-free survival were 78.4%, 68.2%, and 59.7% and
69.6%, 65.3%, and 65.3%, respectively (Figs. 2 and 3). The 1-, 2-,
3-year disease-free survival rates were 68.6%, 64.3%, and 64.3%,
respectively (Fig. 4). Cox proportional hazard model analysis
showed that the time interval to recurrence and histology were
independent prognostic factors for overall survival (P,0.05)
(Table 1). Overall survival was worse when the time interval
between initial treatment and recurrence was less than 2 years
(p=0.013) and with non-squamous carcinoma (p=0.012).
Toxicity
Grade 5 acute toxicity was not observed. Nine patients
developed grade 3 leukopenia and recovered quickly after the
administration of G-CSF (granulocyte-colony stimulating factor).
No patient developed grade 3 or greater acute gastrointestinal (GI)
toxicity or genitourinary toxicity.
As for late toxicity, 7 patients developed Grade 2 proctitis, 1
patient had Grade 3 proctitis requiring surgical intervention, and 1
patient had Grade 3 intestinal obstruction and was treated with
conventionally fractionated 60 Gy to the enlarged para-aortic
lymph nodes. Grade 2 hematuria was observed in 3 patients
(Table 2).
Discussion
Although reports on 3D-RT or IMRT have been increasingly
published in recent years, majority of studies have focused on
Figure 1. Overall survival after radiotherapy for recurrent and metastatic cervical cancer.
doi:10.1371/journal.pone.0040299.g001
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radical surgery, while few have addressed recurrent and metastatic
disease. According to a retrospective review of more than 526
patients with invasive cervical cancer, 31% developed tumor
recurrence, of which 58% recurred within 1 year and 76% within
2 years [6]. In the present study, the 1-year recurrence rate of 54%
was in agreement with the previous reports, but only 32% patients
showed recurrence within 2 years. The reported survival rates in
patients with local recurrence of cervical cancer after a radical
surgery range from 6% to 77%; moreover, patients with central
recurrences had better prognoses than those with pelvic side wall
recurrence [7,8,9,10]. Median survival after diagnosis of re-
currence was reported to be 9.8,15 months [11,12]. Tumor size
was also an important prognostic factor, and more than 5-year
survival was not observed in patients with tumor size of $3c m
[10]. The present study included 39 patients with bulky re-
currence. The 3-year overall survival and locoregional control
were 56.1% and 59.7%, respectively. Based on the benefits of 3D-
RT or IMRT mentioned above, it is yet to be determined whether
5-year survival would be similar or even superior to the 3-year
survival assessed in this study.
A study by Piver et al. reported a 5-year survival rate of only
9.6%, with death rates of 16.1% from complications and 74.1%
from cancer. The intestinal complication rate in patients who
received 6,000 cGy of split-course irradiation in 8 weeks was
61.9% and only 10.0% in the patients who primarily received
4,400–5,000 cGy in 4.5–5 weeks [13]. The result of RTOG 92-10
showed that twice-daily fractionation of PALN irradiation
combined with CTX is highly toxic, resulting in an unacceptably
high rate (17%, 5 of 29) of Grade 4 late toxicity. One patient died
of acute complications of the therapy [14]. However, in
comparison to PALN conventional radiation techniques, PALN-
IMRT is feasible because of significant sparing of the critical
normal structures [15,16]. The radiation dose to the GTV was
escalated from the conventional 45–60 Gy, whereas the PTV
region received 45 Gy [17]. Eight patients in our study were
treated with PALN-IMRT, with a median dose to PTV of 50 Gy.
Of these, 3 patients developed grade 3 leukopenia and 1 patient
Figure 2. Local control after radiotherapy for recurrent and metastatic cervical cancer.
doi:10.1371/journal.pone.0040299.g002
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radiotherapy.
Stereotactic body radiotherapy (SBRT) is another treatment
planning which results in high target dose and steep dose gradients
beyond the target, and therefore, SBRT can deliver higher doses
to tumors and causes less normal tissue damage. Recent years,
there is a growing evidence of using stereotactic body radiotherapy
for recurrent cervical cancers. Deodato et al. reported a case series
of SBRT in recurrent gynecological cancer. 11 patients (12 lesions)
were given a dose of 30 Gy in five fractions. After a median follow-
up of 19 months, 7 patients (63%) experienced local and/or
distant progression of disease. The 2-year local progression-free
survival was 81.8%, while the 2-year metastases-free survival was
54.4%. Acute and late toxicities were grade 2 or less [18]. Due to
large size of the recurrent cancer (median 4.5 cm) and peripheral
location (n=12), SBRT (median 3 fractions of 5 Gy to 65%) was
used for local dose escalation after 50 Gy conventionally
fractionated radiotherapy within all 19 patients (cervical cancer
n=12, endometrial cancer n=7) in Guckenberger et al.’s report.
3-year overall survival was 34% with systemic progression the
leading cause of death (7/10) after median follow-up of 22 months.
3-year local control rate was 81%. The rate of late toxicity .
grade II was 25% at 3 years [19]. Despite the growing interest,
there is very limited clinical data in the literature on SBRT for
recurrent cervical cancer. Most reports have small sample sizes.
No definite ‘‘optimal’’ SBRT single fraction dose and total dose
have been achieved. Further studies on dose–response relationship
are needed to evaluate the effectiveness and toxicity in recurrent
cervical cancer.
In this retrospective study, we mainly used platinum-based
chemotherapy. In 1999, the US National Cancer Institute
recommendedusingcisplatin-basedchemotherapyduringradiation
for cervical cancer based on several cooperative clinical trials that
demonstratedthebenefitoftheconcurrentuseofchemotherapyand
radiation to treat locally advanced and high-risk cervical cancer
[20,21,22,23,24]. Nedaplatin, a second-generation platinum com-
plex, is considered to have equivalent or more pronounced activity
against solid tumors but less nephrotoxicity and gastrointestinal
toxicitythancisplatinand,therefore,couldbeusedasasubstitutefor
cisplatin in the treatment of cervical cancer [25,26]. The addition,
Figure 3. Progression-free survival after radiotherapy for recurrent and metastatic cervical cancer.
doi:10.1371/journal.pone.0040299.g003
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molecules as compared to platinum, may have an additive or even
a synergistic anticancer effect [27]. In a phase II study, we reported
thattheuseofpaclitaxel(35 mg/m
2)andnedaplatin(20 mg/m
2)for
concurrent chemoradiotherapy CCRT was effective and well
tolerated [28]. In our study, concurrent platinum-based chemo-
therapy, with cisplatin/nedaplatin or cisplatin plus paclitaxel as the
most common compounds, was administered in 38 patients.
However, platinum-based chemotherapy did not significantly affect
Figure 4. Disease-free survival after radiotherapy for recurrent and metastatic cervical cancer.
doi:10.1371/journal.pone.0040299.g004
Table 1. Cox proportional hazard model analysis of variables
predicting the overall survival.
P RR 95.0% CI
Age 0.533 1.028 0.942,1.122
Time interval 0.039 0.917 0.845,0.996
Salvage surger 0.118 0.155 0.015,1.601
Concurrent chemotherapy 0.554 0.671 0.180,2.508
Tumor size 0.183 1.187 0.922,1.528
Histology 0.012 0.162 0.039,0.669
doi:10.1371/journal.pone.0040299.t001
Table 2. Grade 3 acute toxicity during and up to 6 months
after radiotherapy, and late treatment-related toxicities more
than 6 months after the radiotherapy.
No chemotherapy With chemotherapy
Acute toxicity
Leukopenia 3 6
Late toxicity
Proctitis 1
Intestinal
obstruction
1
doi:10.1371/journal.pone.0040299.t002
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p=0.554, respectively). Low statistical power associated with small
sample size may be a contributing factor. In our analysis of other
predictivefactors,thetimeintervalofrecurrenceandhistologywere
found to be statistically significant factors. However, the role of age,
salvage surgery, and tumor size has not yet been well established.
Multiple studies on 3D-RT or IMRT have been performed in
patients with cervical cancer that showed the clinical benefits of
3D-RT or IMRT, such as reduction in acute gastrointestinal and
hematologic toxicity, over the conventional EBRT. Yamazaki
et al. reported that bowel complications reduced from 17.5% to
2.9% and leg edema from 28.6% to 3.1% after using 3D-RT
during the postoperative radiotherapy for cervical cancer as
compared to parallel-opposed fields [29]. Grade 2 acute gastro-
intestinal toxicity was 60% vs. 91% (p=0.002) in Mundt et al.’s
retrospective study that compared 40 gynecology patients who
underwent IMRT of which 35 were previously treated with
conventional EBRT. Grade 3 toxicity did not develop in any of the
patients. No or only infrequent antidiarrheal medications were
needed (75% vs. 34%, p=0.001). Grade 2 genitourinary
morbidity was reduced from 20% to 10% after administration of
IMRT [30], and chronic GI toxicity was 11.1% vs. 50.0%,
(p=0.001) [31]. In Roeske’s analysis, the most significant factor
that was correlated with acute GI toxicity was the volume of small
bowel receiving the prescription dose of 45 Gy [32]. IMRT is also
a good means of reducing hematological toxicity, because 40% of
the total body bone marrow reserve lies within the pelvic bones.
Meanwhile, concurrent chemoradiotherapy has become a standard
treatment for locally advanced cervical cancer. Moreover, the use
of concurrent chemotherapy increases the likelihood of developing
clinical myelotoxicity. Patients using intensity-modulated whole
pelvic radiotherapy experienced lesser Grade 2 or greater WBC
toxicity than conventional whole pelvic radiotherapy (31.2% vs.
60%, p=0.08) [33], which provides the opportunity for additional
use of novel systemic therapies. In our study, 9 (18%) patients
developed grade 3 leukopenia, which occurred less frequently and
showed a faster recovery after the administration of G-CSF. Nine
(18%) patients developed Grade 2 or higher late GI toxicity,
including 1 patient who developed Grade 3 proctitis requiring
surgical intervention and 1 patient who developed Grade 3
intestinal obstruction. These rates are slightly higher than those
reported previously [31] but appeared to be acceptable when the
median dose prescribed for the PTV is considered. Based on the
rather short follow-up of our patients, the true incidence of late
toxicity may be underestimated. Therefore, long-term follow-up
studies are needed to confirm these results.
3D-RT or IMRT for recurrent and metastatic cervical cancer is
an effective treatment method with a 3-year overall survival rate of
56.1% and an acceptable level of complications. Longer follow-up
and further studies are needed to confirm the role of 3D-RT or
IMRT in the multimodality management of the disease.
Materials and Methods
All of the procedures were done in accordance with the
Declaration of Helsinki and relevant policies in China. The study
obtained ethics approval for my study from the ethics committee of
Shanghai Cancer Hospital of Fudan University. We obtained the
informed consent from all participants involved in our study.
Patient Characteristics
Between March 2007 and December 2010, 50 patients with
recurrent cervical and metastatic cancer were treated with 3D-RT
or IMRT. The patient characteristics are summarized in Table 3.
The median interval to recurrence or metastases was 12 months
(range, 6–51 months). Because of difficulties in obtaining
a histological diagnosis, all the patients underwent physical
examination, computed tomography (CT), and/or magnetic
resonance imaging (MRI) of the chest, abdomen, and pelvic
cavity before the treatment. Certain patients underwent positron
emission tomography (PET) for a general evaluation. Surgery was
performed before irradiation in 5 patients (10%). Sixteen patients
(32%) underwent 3D-RT, and 34 patients (68%) received IMRT.
Induction chemotherapy was administered in 3 patients
(nedaplatin and paclitaxel, n=2; nedaplatin and cyclophospha-
mide, n=1), and concurrent platinum-based chemotherapy was
administered in 38 patients (76%) (weekly cisplatin (30 mg/m
2),
n=9; weekly cisplatin and paclitaxel (30 mg/m
2), n=15; weekly
nedaplatin (20 mg/m
2), n=7; 3-weekly cisplatin (80 mg/m
2) and
paclitaxel (135 mg/m
2), n=7).
Target Definition
Contrast-enhanced planning CT of the pelvic or abdominal
region was performed in the treatment position. Targets and
organs at risk (OARs) were delineated on axial CT slices. A 7-mm
isotropic expansion of the gross tumor volume (GTV) encompass-
ing the tumor and/or pathological lymph nodes gave the clinical
target volume (CTV). In patients who had undergone a surgery,
the CTV encompassed the postoperative tumor bed. The CTV
was expanded isotropically with an 8 -mm margin to yield
a planning target volume (PTV). The spinal cord, kidney, small
Table 3. Patient characteristics.
Characteristics N=50 %
Age (years)
Average 43
Range 27–73
Histology
Squamous cell carcinoma 43 86
Adenocarcinoma 2 4
Adenosquamous cell carcinoma 4 8
Mucinous adenocarcinoma 1 2
Prior treatment
Surgery 31 62
Surgery and adjuvant chemotherapy 12 24
Surgery and adjuvant radiotherapy 4 8
Surgery and adjuvant chemoradiotherapy 3 6
Site of recurrence or metastases
Pelvic wall recurrence 23 46
Central recurrence 17 34
PALN metastases 5 10
Pelvic wall recurrence and PALN
metastases
24
Central recurrence and PALN metastases 1 2
Central recurrence and ILN metastases 2 4
Size of the pelvic recurrence
,3c m 6 1 2
.=3 cm 39 78
Abbreviations: PALN: Para-aortic lymph nodes; ILN: Inguinal lymph nodes.
doi:10.1371/journal.pone.0040299.t003
Radiation Therapy for Cervical Cancer
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40299bowel, bladder, rectum, and caput femoris were outlined as the
OARs.
Direct tumor boost is an attractive method for the treatment of
recurrent and metastatic cervical cancer that allows the mainte-
nance of standard doses and fractionation to the areas of potential
microscopic spread while improving the therapeutic ratio by
delivering a higher total dose to all of the macroscopic disease.
Patients can be treated with IMRT for the initial treatment
volume (PTV1) followed by a direct IMRT booster dose delivered
to a smaller volume (PTV2).
Dose Prescription, Treatment Planning, and Delivery
ForthePTVencompassingthemacroscopictumor,amediandose
of 60 Gy in 30 fractions and 45 or 50 Gy in 25 fractions was
prescribedforpelvicrecurrenceandpara-aorticlymphnodesPALN
metastasis, respectively. The prescribed dose for direct tumor boost
was12or14 Gywithasingledoseof2 GyforPTV2after45or50 Gy
in25fractionsgivenforPTV1.Thisdosingstrategyaimedtodeliver
atleast95%oftheprescribeddosetoatleast95%ofthePTVandnot
more than 105% of the prescribed dose to not more than 1% of the
PTV. A maximum cumulative dose constraint of 40 Gy was
implemented for the spinal cord. Treatment was delivered using 6-
MV photonbeams from a linear accelerator.
Follow-up and Statistical Analysis
During radiotherapy, all the patients were followed up at least
once weekly. Acute toxicity was assessed according to the
Common Toxicity Criteria (CTC) version 2.0; for late radiother-
apy toxicity, the RTOG (Radiation Therapy Oncology Group)
criteria were used.
The endpoint for time-to-event analysis was the overall survival
(death from any cause), which was calculated using the Kaplan–
Meier method. Local tumor control was defined as tumor
shrinkage and no tumor progression during follow-up. Determi-
nation of local control required CT or MRI imaging and
gynecological examination. Progression-free survival (freedom
from disease progression) and disease-free survival (free of residual
disease) were also calculated. All the events were measured from
the first day of radiotherapy to the date of tumor occurrence or the
last follow-up for the censored observations. All the analyses were
performed using SPSS 15.0 software.
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